semaglutide and mcas Not all GLP-1s work the same way for MCAS. Most patients do better on Tirzepatide, the dual incretin with both GLP-1 GIP receptor agonists. But some mast cells just respond better NW Integrative Medicine: Semaglutide Treatment

doi: 10.1016/j.indcrop.2019.111498 160

As female-physiology body composition research has matured, two compounds have emerged as the dominant reference points for investigating visceral fat specifically: Tesamorelin, a stabilized Growth Hormone Releasing Hormone (GHRH) analog with a uniquely well-documented visceral-fat research profile, and Retatrutide, an engineered triple agonist peptide studied for aggressive, multi-pathway metabolic effects

Reports indicate that the incidence correlates with higher dosing, and onset occurs within the first month of therapy and upon dose escalation

Our results suggest that the responses to GEP44 are most likely mediated via integrated responses from several tissues